DNA repair targeted therapy: The past or future of cancer treatment?

[1]  Emidio Camaioni,et al.  Concepts and Molecular Aspects in the Polypharmacology of PARP‐1 Inhibitors , 2016, ChemMedChem.

[2]  T. Yoshino,et al.  Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors , 2015, Anti-cancer drugs.

[3]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[4]  T. Conrads,et al.  The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo , 2015, Oncotarget.

[5]  D. Melton,et al.  Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF. , 2015, Bioorganic & medicinal chemistry letters.

[6]  Lara E Sucheston-Campbell,et al.  Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Antonella Isacchi,et al.  Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy. , 2015, Journal of medicinal chemistry.

[8]  J. Hays,et al.  Pharmacogenomics and Personalized Medicine Dovepress Olaparib in the Management of Ovarian Cancer , 2022 .

[9]  S. Gabriel,et al.  A Dominant Mutation in Human RAD51 Reveals Its Function in DNA Interstrand Crosslink Repair Independent of Homologous Recombination. , 2015, Molecular cell.

[10]  J. Dempsey,et al.  LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms , 2015, Molecular Cancer Therapeutics.

[11]  S. Shave,et al.  Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance. , 2015, DNA repair.

[12]  P. Glazer,et al.  YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors , 2015, Molecular Cancer Research.

[13]  Shufeng Zhou,et al.  Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer , 2015, Drug design, development and therapy.

[14]  Wen-Hwa Lee,et al.  Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors. , 2015, European journal of medicinal chemistry.

[15]  A. Ryan,et al.  ATM and ATR as therapeutic targets in cancer. , 2015, Pharmacology & therapeutics.

[16]  R. Hromas,et al.  NSC666715 and Its Analogs Inhibit Strand-Displacement Activity of DNA Polymerase β and Potentiate Temozolomide-Induced DNA Damage, Senescence and Apoptosis in Colorectal Cancer Cells , 2015, PloS one.

[17]  Natalia N. Ivanova,et al.  Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells , 2015, Nature Biotechnology.

[18]  A. Venook,et al.  Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Weichselbaum,et al.  RAD54 family translocases counter genotoxic effects of RAD51 in human tumor cells , 2015, Nucleic acids research.

[20]  H. Ploegh,et al.  Inhibition of non-homologous end joining increases the efficiency of CRISPR/Cas9-mediated precise [TM: inserted] genome editing , 2015, Nature Biotechnology.

[21]  S. Yao,et al.  A small-molecule protein-protein interaction inhibitor of PARP1 that targets its BRCT domain. , 2015, Angewandte Chemie.

[22]  S. Fesik,et al.  Diphenylpyrazoles as replication protein a inhibitors. , 2015, ACS medicinal chemistry letters.

[23]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Alan Ashworth,et al.  Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. , 2015, Annual review of medicine.

[25]  J. Bartek,et al.  Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring. , 2015, Journal of medicinal chemistry.

[26]  H. Kluger,et al.  Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair Inhibitors , 2014, Molecular Cancer Therapeutics.

[27]  V. Semiglazov,et al.  Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens. , 2014, Clinical breast cancer.

[28]  S. Ayyadevara,et al.  A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin , 2014, Front. Oncol..

[29]  L. Rangell,et al.  Depletion of the Central Metabolite NAD Leads to Oncosis-mediated Cell Death* , 2014, The Journal of Biological Chemistry.

[30]  Gagandeep Kaur,et al.  DNA repair and redox activities and inhibitors of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1): a comparative analysis and their scope and limitations toward anticancer drug development. , 2014, Journal of medicinal chemistry.

[31]  K. Knudsen,et al.  Beyond DNA repair: DNA-PK function in cancer. , 2014, Cancer discovery.

[32]  G. Oakley,et al.  RPA inhibition increases replication stress and suppresses tumor growth. , 2014, Cancer research.

[33]  C. Sessa,et al.  Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours , 2014, British Journal of Cancer.

[34]  R. Weichselbaum,et al.  The RAD51-stimulatory compound RS-1 can exploit the RAD51 overexpression that exists in cancer cells and tumors. , 2014, Cancer research.

[35]  T. Dawson,et al.  Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis , 2014, Proceedings of the National Academy of Sciences.

[36]  S. Wallace.  Base excision repair: a critical player in many games. , 2014, DNA repair.

[37]  P. Iversen,et al.  Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer , 2014, Investigational New Drugs.

[38]  Dong Wang,et al.  Identification of a novel potential antitumor activity of gossypol as an APE1/Ref-1 inhibitor , 2014, Drug design, development and therapy.

[39]  U. Matulonis,et al.  PARP inhibitors in ovarian cancer: current status and future promise. , 2014, Gynecologic oncology.

[40]  S. Lakhani,et al.  Rad51 supports triple negative breast cancer metastasis , 2014, Oncotarget.

[41]  G. Ball,et al.  Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy , 2014, Oncotarget.

[42]  R. Beckmann,et al.  CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy. , 2014, Pharmacology & therapeutics.

[43]  K. O'Byrne,et al.  Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the Promising , 2014, Front. Oncol..

[44]  A. Venkitaraman.  Cancer Suppression by the Chromosome Custodians, BRCA1 and BRCA2 , 2014, Science.

[45]  J. Mestres,et al.  Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors , 2014, Oncotarget.

[46]  M. Hedayati,et al.  Irreversible inhibition of DNA polymerase β by small-molecule mimics of a DNA lesion. , 2014, Journal of the American Chemical Society.

[47]  Stephen W. Fesik,et al.  Discovery of a Potent Stapled Helix Peptide That Binds to the 70N Domain of Replication Protein A , 2014, Journal of medicinal chemistry.

[48]  R. Muschel,et al.  Targeting ATR in DNA damage response and cancer therapeutics. , 2014, Cancer treatment reviews.

[49]  F. Sugawara,et al.  Formosusin A, a novel specific inhibitor of mammalian DNA polymerase β from the fungus Paecilomyces formosus. , 2014, Bioorganic & medicinal chemistry.

[50]  John A Tainer,et al.  DNA double-strand break repair pathway choice is directed by distinct MRE11 nuclease activities. , 2014, Molecular cell.

[51]  Y. Pommier,et al.  Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib , 2013, Molecular Cancer Therapeutics.

[52]  D. Beer,et al.  CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells. , 2013, Lung cancer.

[53]  Sheena M. Scroggins,et al.  Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas , 2013, Clinical Cancer Research.

[54]  Ying Feng,et al.  Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[55]  E. Winer,et al.  A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. , 2013, European journal of cancer.

[56]  Manash S. Chatterjee,et al.  The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. , 2013, The Lancet. Oncology.

[57]  Xiaojin Shi,et al.  Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours , 2013, Cancer Chemotherapy and Pharmacology.

[58]  Antai Wang,et al.  Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine , 2013, Journal of cellular and molecular medicine.

[59]  D. Wishart,et al.  Small Molecule Inhibitors of ERCC1-XPF Protein-Protein Interaction Synergize Alkylating Agents in Cancer Cells , 2013, Molecular Pharmacology.

[60]  Daria M. Tanska,et al.  Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776 , 2013, Clinical Cancer Research.

[61]  D. Koshland,et al.  The homologous recombination machinery modulates the formation of RNA–DNA hybrids and associated chromosome instability , 2013, eLife.

[62]  Mo Li,et al.  Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. , 2013, Cancer cell.

[63]  G. Sauter,et al.  RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma , 2013, International journal of cancer.

[64]  N. Mukhopadhyay,et al.  ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation , 2013, Clinical Cancer Research.

[65]  N. Curtin,et al.  Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer , 2013, Molecular Cancer Therapeutics.

[66]  X. Jacq,et al.  Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. , 2013, Journal of medicinal chemistry.

[67]  J. Turchi,et al.  Chemotherapy induced DNA damage response , 2013, Cancer biology & therapy.

[68]  G. Weiss,et al.  Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer , 2013, Investigational New Drugs.

[69]  Phang-lang Chen,et al.  A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia , 2013, EMBO molecular medicine.

[70]  H. Yoshida,et al.  Inhibitory effect of novel somatostatin peptide analogues on human cancer cell growth based on the selective inhibition of DNA polymerase β. , 2013, Bioorganic & medicinal chemistry.

[71]  A. Kozikowski,et al.  An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. , 2013, Journal of medicinal chemistry.

[72]  G. Oakley,et al.  A small molecule directly inhibits the p53 transactivation domain from binding to replication protein A , 2012, Nucleic acids research.

[73]  A. De,et al.  An Inhibitor of Nonhomologous End-Joining Abrogates Double-Strand Break Repair and Impedes Cancer Progression , 2012, Cell.

[74]  D. Wishart,et al.  Virtual Screening and Biological Evaluation of Inhibitors Targeting the XPA-ERCC1 Interaction , 2012, PloS one.

[75]  L. Panasci,et al.  Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond , 2012, Front. Pharmacol..

[76]  Y. Pommier,et al.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.

[77]  Murray N. Robertson,et al.  Synthesis, DNA-PK inhibition, anti-platelet activity studies of 2-(N-substituted-3-aminopyridine)-substituted-1,3-benzoxazines and DNA-PK and PI3K inhibition, homology modelling studies of 2-morpholino-(7,8-di and 8-substituted)-1,3-benzoxazines. , 2012, European journal of medicinal chemistry.

[78]  David M. Wilson,et al.  Diverse Small Molecule Inhibitors of Human Apurinic/Apyrimidinic Endonuclease APE1 Identified from a Screen of a Large Public Collection , 2012, PloS one.

[79]  M. Walton,et al.  Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors , 2012, Journal of medicinal chemistry.

[80]  N. Pavletich,et al.  Structure and conformational change of a replication protein A heterotrimer bound to ssDNA. , 2012, Genes & development.

[81]  S. Boulton,et al.  Playing the end game: DNA double-strand break repair pathway choice. , 2012, Molecular cell.

[82]  Lirong Wang,et al.  Identification and characterization of human apurinic/apyrimidinic endonuclease-1 inhibitors. , 2012, Biochemistry.

[83]  J. Tuszynski,et al.  DNA polymerase beta (pol β) inhibitors: a comprehensive overview. , 2012, Drug discovery today.

[84]  R. Muschel,et al.  The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy , 2012, Cancer biology & therapy.

[85]  Yunfeng Pan,et al.  Inhibition of Non-Homologous End Joining Repair Impairs Pancreatic Cancer Growth and Enhances Radiation Response , 2012, PloS one.

[86]  C. Sears,et al.  Complex Cisplatin-Double Strand Break (DSB) Lesions Directly Impair Cellular Non-Homologous End-Joining (NHEJ) Independent of Downstream Damage Response (DDR) Pathways* , 2012, The Journal of Biological Chemistry.

[87]  N. Curtin,et al.  Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K , 2012, Molecular Cancer Therapeutics.

[88]  Jeremy M. Stark,et al.  RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells , 2012, Nucleic acids research.

[89]  David M. Wilson,et al.  Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors. , 2012, Journal of medicinal chemistry.

[90]  N. Curtin,et al.  The role of PARP in DNA repair and its therapeutic exploitation , 2011, British Journal of Cancer.

[91]  R. Bristow,et al.  The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[92]  H. Mackay,et al.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.

[93]  S. Jalal,et al.  Novel Irreversible Small Molecule Inhibitors of Replication Protein A Display Single-Agent Activity and Synergize with Cisplatin , 2011, Molecular Cancer Therapeutics.

[94]  Haiyang Guo,et al.  Berberine Radiosensitizes Human Esophageal Cancer Cells by Downregulating Homologous Recombination Repair Protein RAD51 , 2011, PloS one.

[95]  Lesley A. Mathews,et al.  Increased Expression of DNA Repair Genes in Invasive Human Pancreatic Cancer Cells , 2011, Pancreas.

[96]  Robert W Sobol,et al.  Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. , 2011, Antioxidants & redox signaling.

[97]  M. Garrett,et al.  Anticancer therapy with checkpoint inhibitors: what, where and when? , 2011, Trends in pharmacological sciences.

[98]  G. Oakley,et al.  Small molecule inhibitor of the RPA70 N-terminal protein interaction domain discovered using in silico and in vitro methods. , 2011, Bioorganic & medicinal chemistry.

[99]  Sanjeev Banerjee,et al.  Abstract 3524: Structure-based molecular docking of DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer , 2011 .

[100]  H. Kurumizaka,et al.  Halenaquinone, a chemical compound that specifically inhibits the secondary DNA binding of RAD51 , 2011, Genes to cells : devoted to molecular & cellular mechanisms.

[101]  Fiona A. Stewart,et al.  Strategies to improve radiotherapy with targeted drugs , 2011, Nature Reviews Cancer.

[102]  N. Munshi,et al.  Genomic evolution in Barrett’s adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome , 2011, Oncogene.

[103]  Scott H. Kaufmann,et al.  Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells , 2011, Proceedings of the National Academy of Sciences.

[104]  I. Hardcastle,et al.  DNA-dependent protein kinase (DNA-PK) inhibitors: structure-activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain. , 2011, Bioorganic & medicinal chemistry letters.

[105]  L. Pearl,et al.  Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2. , 2011, Journal of medicinal chemistry.

[106]  L. Dekker,et al.  Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines , 2011, British Journal of Cancer.

[107]  L. Pearl,et al.  CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. , 2011, Cancer research.

[108]  Tianhong Li,et al.  A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial , 2010, Investigational New Drugs.

[109]  J. Turchi,et al.  Identification of novel small molecule inhibitors of the XPA protein using in silico based screening. , 2010, ACS chemical biology.

[110]  D. Delia,et al.  A protein phosphatase feedback mechanism regulates the basal phosphorylation of Chk2 kinase in the absence of DNA damage. , 2010, Biochimica et biophysica acta.

[111]  A. Ashworth,et al.  A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2010, Clinical Cancer Research.

[112]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[113]  W. Kraus,et al.  The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. , 2010, Molecular cell.

[114]  S. Patrick,et al.  Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. , 2010, DNA repair.

[115]  J. Turchi,et al.  Purification and characterization of exonuclease-free Artemis: Implications for DNA-PK-dependent processing of DNA termini in NHEJ-catalyzed DSB repair. , 2010, DNA repair.

[116]  Jan Lubinski,et al.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  K. Aziz,et al.  DNA-PKcs deficiency leads to persistence of oxidatively induced clustered DNA lesions in human tumor cells. , 2010, Free radical biology & medicine.

[118]  J. Turchi,et al.  Targeted inhibition of Replication Protein A reveals cytotoxic activity, synergy with chemotherapeutic DNA-damaging agents, and insight into cellular function. , 2010, Cancer research.

[119]  S. Kaufmann,et al.  PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.

[120]  B. L. Sibanda,et al.  Crystal Structure of DNA-PKcs Reveals a Large Open-Ring Cradle Comprised of HEAT Repeats , 2009, Nature.

[121]  P. Jeggo,et al.  Cellular radiosensitivity: How much better do we understand it? , 2009, International journal of radiation biology.

[122]  Sanjeev Banerjee,et al.  A Novel Inhibitor of DNA Polymerase β Enhances the Ability of Temozolomide to Impair the Growth of Colon Cancer Cells , 2009, Molecular Cancer Research.

[123]  R. Eeles,et al.  Overexpression of RAD51 occurs in aggressive prostatic cancer , 2009, Histopathology.

[124]  K. Valerie,et al.  Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion , 2009, Molecular Cancer Therapeutics.

[125]  M. Weinfeld,et al.  Identification of a small molecule inhibitor of the human DNA repair enzyme polynucleotide kinase/phosphatase. , 2009, Cancer research.

[126]  R. Dhir,et al.  Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. , 2009, Cancer research.

[127]  T. Shibata,et al.  DIDS, a chemical compound that inhibits RAD51-mediated homologous pairing and strand exchange , 2009, Nucleic acids research.

[128]  N. Munshi,et al.  Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. , 2009, Blood.

[129]  A. Mason,et al.  Cellular Functions of Human RPA1 , 2008, Journal of Biological Chemistry.

[130]  P. Sung,et al.  Mechanism of eukaryotic homologous recombination. , 2008, Annual review of biochemistry.

[131]  H. Klein,et al.  The consequences of Rad51 overexpression for normal and tumor cells. , 2008, DNA repair.

[132]  Alexander D. MacKerell,et al.  Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. , 2008, Cancer research.

[133]  J. Yélamos,et al.  Toward specific functions of poly(ADP-ribose) polymerase-2. , 2008, Trends in molecular medicine.

[134]  L. Kopelovich,et al.  A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. , 2008, Nature chemical biology.

[135]  H. Naegeli,et al.  DNA repair triggered by sensors of helical dynamics. , 2007, Trends in biochemical sciences.

[136]  N. Curtin,et al.  PARP inhibitor development for systemic cancer targeting. , 2007, Anti-cancer agents in medicinal chemistry.

[137]  Y. Maehara,et al.  Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non‐small cell lung cancer , 2007, International journal of cancer.

[138]  J. Allalunis-Turner,et al.  Human polynucleotide kinase participates in repair of DNA double-strand breaks by nonhomologous end joining but not homologous recombination. , 2007, Cancer research.

[139]  Shu-Feng Zhou.  ERCC1 and non-small-cell lung cancer. , 2007, The New England journal of medicine.

[140]  R. Wood,et al.  ERCC1 and non-small-cell lung cancer [8] , 2007 .

[141]  Dihua Yu,et al.  Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation , 2007, Molecular Cancer Therapeutics.

[142]  Giovanni Parmigiani,et al.  Meta-analysis of BRCA1 and BRCA2 penetrance. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  J. Wu,et al.  Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2 , 2007, Molecular Cancer Therapeutics.

[144]  L. Povirk.  Biochemical mechanisms of chromosomal translocations resulting from DNA double-strand breaks. , 2006, DNA repair.

[145]  N. Curtin,et al.  Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. , 2006, Cancer research.

[146]  P. Workman,et al.  Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026 , 2005, British Journal of Cancer.

[147]  M. Sternberg,et al.  Isolation of a small molecule inhibitor of DNA base excision repair , 2005, Nucleic acids research.

[148]  W. Zhong,et al.  High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients , 2005, British Journal of Cancer.

[149]  J. Turchi,et al.  Cisplatin Sensitizes Cancer Cells to Ionizing Radiation via Inhibition of Nonhomologous End Joining , 2005, Molecular Cancer Research.

[150]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[151]  P. Jeggo,et al.  The life and death of DNA-PK , 2005, Oncogene.

[152]  I. Hardcastle,et al.  Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. , 2004, Bioorganic & medicinal chemistry letters.

[153]  N. Curtin,et al.  Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM , 2004, Cancer Research.

[154]  Huichen Wang,et al.  ATR Affecting Cell Radiosensitivity Is Dependent on Homologous Recombination Repair but Independent of Nonhomologous End Joining , 2004, Cancer Research.

[155]  M. Tilby,et al.  A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. , 2004, Blood.

[156]  L. Créancier,et al.  Decreased Nucleotide Excision Repair Activity and Alterations of Topoisomerase IIα Are Associated with the in Vivo Resistance of a P388 Leukemia Subline to F11782, a Novel Catalytic Inhibitor of Topoisomerases I and II , 2004, Clinical Cancer Research.

[157]  J. Turchi,et al.  Development of a high-throughput screen for inhibitors of replication protein A and its role in nucleotide excision repair. , 2004, Molecular cancer therapeutics.

[158]  John Calvin Reed,et al.  Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. , 2003, Journal of medicinal chemistry.

[159]  David Lombard,et al.  Defective DNA Repair and Increased Genomic Instability in Artemis-deficient Murine Cells , 2003, The Journal of experimental medicine.

[160]  E. Pastwa,et al.  Repair of Radiation-Induced DNA Double-Strand Breaks is Dependent upon Radiation Quality and the Structural Complexity of Double-Strand Breaks , 2003, Radiation research.

[161]  A. Chiarugi.  Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited. , 2002, Trends in pharmacological sciences.

[162]  A. McCullough,et al.  Nucleotide Excision Repair in E. Coli a , 1994, Annals of the New York Academy of Sciences.

[163]  D. Seckinger,et al.  Inhibition of DNA repair in cells treated with a combination of alkylating agents. , 1993, Anticancer research.

[164]  J. Turchi,et al.  Chemical inhibitor targeting the replication protein A-DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer. , 2015, Biochemical pharmacology.

[165]  H. Mackay,et al.  Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. , 2015, The Lancet. Oncology.

[166]  M. Piccart,et al.  An update on PARP inhibitors—moving to the adjuvant setting , 2015, Nature Reviews Clinical Oncology.

[167]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[168]  N. Neamati,et al.  Small-molecule inhibitors of APE1 DNA repair function: an overview. , 2012, Current molecular pharmacology.

[169]  M. Georgiadis,et al.  APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. , 2012, Current molecular pharmacology.

[170]  J. Yélamos,et al.  PARP-1 and PARP-2: New players in tumour development. , 2011, American journal of cancer research.

[171]  T. Fischmann,et al.  Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2. , 2011, Bioorganic & medicinal chemistry letters.

[172]  T. Fischmann,et al.  Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1. , 2011, Bioorganic & medicinal chemistry letters.

[173]  A. Sancar,et al.  Nucleotide excision repair in E. coli and man. , 2004, Advances in protein chemistry.

[174]  S. Freier,et al.  Elevated levels of Rad51 recombination protein in tumor cells. , 2002, Cancer research.

[175]  Y. Li,et al.  Expression of ATM in ataxia telangiectasia fibroblasts rescues defects in DNA double‐strand break repair in nuclear extracts , 2001, Environmental and molecular mutagenesis.

[176]  E. Katz,et al.  The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells. , 1990, Cancer communications.